Travere Therapeutics (TVTX) Other Gross PP&E Adjustments (2016 - 2025)
Historic Other Gross PP&E Adjustments for Travere Therapeutics (TVTX) over the last 11 years, with Q3 2025 value amounting to -$11.5 million.
- Travere Therapeutics' Other Gross PP&E Adjustments rose 2680.37% to -$11.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$11.5 million, marking a year-over-year increase of 2680.37%. This contributed to the annual value of -$15.9 million for FY2024, which is 3581.18% up from last year.
- Travere Therapeutics' Other Gross PP&E Adjustments amounted to -$11.5 million in Q3 2025, which was up 2680.37% from -$12.3 million recorded in Q2 2025.
- In the past 5 years, Travere Therapeutics' Other Gross PP&E Adjustments ranged from a high of -$11.5 million in Q3 2025 and a low of -$29.7 million during Q4 2022
- Over the past 5 years, Travere Therapeutics' median Other Gross PP&E Adjustments value was -$19.9 million (recorded in 2023), while the average stood at -$19.9 million.
- In the last 5 years, Travere Therapeutics' Other Gross PP&E Adjustments skyrocketed by 3729.57% in 2021 and then tumbled by 978.74% in 2022.
- Over the past 5 years, Travere Therapeutics' Other Gross PP&E Adjustments (Quarter) stood at -$27.0 million in 2021, then dropped by 9.79% to -$29.7 million in 2022, then rose by 16.66% to -$24.7 million in 2023, then skyrocketed by 35.81% to -$15.9 million in 2024, then rose by 27.83% to -$11.5 million in 2025.
- Its Other Gross PP&E Adjustments stands at -$11.5 million for Q3 2025, versus -$12.3 million for Q2 2025 and -$13.2 million for Q1 2025.